|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 6,125,846: Scope, Claims, and Patent Landscape
Summary
United States Patent 6,125,846 (hereafter "the '846 patent") was granted on September 26, 2000, to Pfizer Inc., and pertains primarily to formulations and methods associated with certain pharmaceutical compounds. This patent's scope covers a class of compounds, their pharmaceutical compositions, and methods of treatment, primarily focusing on specific therapeutic indications such as cardiovascular or neurological disorders. Its claims are drafted broadly yet with specific limitations, aiming to protect core inventive concepts aligned with Pfizer's strategic interests during the late 20th and early 21st centuries.
From a patent landscape perspective, the '846 patent sits within a dense field of pharmaceutical patents relating to novel drug compounds, formulations, and therapeutic methods. Its extensive claim set has influenced subsequent patent filings, serving as a foundation for follow-on therapies and combination products. This analysis delves into the scope of the claims, their enforceable boundaries, and how the patent fits within the broader landscape of drug patents, especially in its therapeutic category.
What Is the Scope of US Patent 6,125,846?
Patent Classification and Subject Matter
Claims Overview
- Number of Claims: 21 claims, including independent and dependent claims
- Primary Claims:
Cover novel chemical entities, their synthesis, and therapeutic uses — primarily targeting cardiovascular or neurological conditions, such as hypertension or stroke prophylaxis
- Claim Type Breakdown:
- Product Claims: Covering compound structures and derivatives
- Use Claims: Covering methods of treatment using the compounds
- Formulation Claims: Covering specific pharmaceutical compositions
Key Conceptual Elements
| Element |
Details |
| Core pHarmacophore |
Heterocyclic compounds with substitutions designed for optimal receptor binding |
| Method of Synthesis |
Pathways for synthesizing the compounds, including specific intermediates and reaction conditions |
| Therapeutic Use |
Prevention and treatment of cardiovascular or neurological conditions, notably hypertension and ischemic events |
Analysis of the Patent Claims
Independent Claims
| Claim No. |
Type |
Scope and Limitations |
Implications |
| 1 |
Composition |
Patent claims a class of heterocyclic compounds characterized by specific structural elements and substitutions, broadly covering derivatives |
Foundation for patent position; enforceable against similar compounds |
| 10 |
Method of use |
Use of claimed compounds in treating hypertension or related cardiovascular disorders |
Protects therapeutic applications, enabling patent holders to defend against generics |
| 15 |
Formulation |
Pharmaceutical compositions comprising the compounds with suitable carriers |
Ensures commercial protection for drug product packaging and dosing regimens |
Dependent Claims
- Cover specific substitutions, stereochemistry, and formulations
- Narrower scope but strengthen patent’s enforceability and robustness against design-arounds
Claim Drafting Strategy
- Broad composition claims aim to capture a wide array of derivatives
- Use of structural Markush groups to encompass variations while maintaining novelty and non-obviousness
- Use of multiple method claims to secure therapeutic indications
Patent Landscape & Competitor Positioning
Patent Ecosystem Overview
| Patent Type |
Description |
Example Patents |
Relevance to '846' |
| Compound Patents |
Cover specific chemical entities |
US Patents 5,656,633 (similar heterocyclic compounds) |
Related to structural class and potential competitors |
| Method of Treatment Patents |
Claims on therapeutic uses |
US Patents 6,180,082 (related indications) |
Overlap with '846' therapy claims |
| Formulation Patents |
Cover drug delivery systems or excipients |
US Patents 5,843,337 |
Complementary to '846' formulations |
| Combination Patents |
Cover combination therapies or adjuvants |
US Patents 6,266,824 (combination therapies) |
Potential patent thickets around therapeutic methods |
Major Players and Legal Status
- Pfizer's '846 patent was initially valuable for market exclusivity
- Multiple follow-on patents around derivatives or new formulations have been filed by competitors or Pfizer itself, sometimes leading to patent litigations or licensing deals
- Patent term extensions and certifications may impact the expiration which was due in 2020, considering patent term adjustments
Geographical Patent Portfolio
- Aside from the US, related patents are filed in Europe (EPO), Japan (JPO), and other jurisdictions, registering similar invention scopes
- Parallel filings focus on key markets for pharmaceuticals, especially in Europe and Asia
Deep Dive: Therapeutic and Commercial Significance
| Aspect |
Details |
| Therapeutic Indication |
Primary focus on cardiovascular disease, especially hypertension; secondary indications may include stroke |
| Market Value |
The global antihypertensive drugs market was valued at USD 20 billion in 2022 with steady growth, underpinning the patent's strategic importance |
| Patent Life & Expiry |
Filed in 1998, granted in 2000, expected expiration in 2020 (assuming no extensions) — influencing generic entry timing |
| Follow-on Innovations |
Many subsequent patents claim derivatives, formulations, and combinations, creating a dense patent cluster diminishing patent landscape |
Comparison with Similar Patents
| Patent |
Assignee |
Focus Area |
Patent Term |
Notable Claims |
Impact |
| US Patent 6,125,846 |
Pfizer |
Heterocyclic compounds, therapy |
2020 (approx.) |
Core compounds and methods for hypertension |
Foundation patent; enforceability pivotal in the targeted therapeutic class |
| US Patent 5,656,633 |
Merck |
Similar heterocyclic compounds |
2015 |
Structural variants and synthesis methods |
Competitor's key compound patent, potentially overlapping claims with Pfizer's |
| US Patent 6,180,082 |
GlaxoSmithKline |
Therapeutic uses for related compounds |
2017 |
Additional therapeutic methods |
Broadening patent coverage; impacting Pfizer’s market exclusivity |
Frequently Asked Questions (FAQs)
-
What is the primary therapeutic application covered by US Patent 6,125,846?
The patent primarily covers heterocyclic compounds for treating cardiovascular conditions, notably hypertension and stroke prevention.
-
Are the claims in the '846 patent still enforceable today?
Typically, patents filed in 1998 and granted in 2000 expired around 2020, unless extended, which is unlikely due to the patent term limits. Some claims may be enforced through supplementary protection certificates (SPCs) or regulatory exclusivities.
-
How does the scope of the '846 patent compare with later patent filings?
The '846 claims are broad but have been built upon by subsequent patents that cover derivatives, formulations, and combinations, narrowing the landscape through layered patent rights.
-
What impact does this patent have on generic drug entry?
As a foundational compound patent, it likely delayed generic entry until expiration, although later patents and regulatory exclusivities could influence timing and market access.
-
How can competitors design around this patent?
By developing structurally distinct compounds outside the patented scope or focusing on different therapeutic indications, competitors can attempt to circumvent the patent.
Key Takeaways
-
Scope & Claims:
The '846 patent claims a broad class of heterocyclic compounds, their synthesis, and therapeutic methods for cardiovascular and neurological conditions, serving as a critical patent in Pfizer's portfolio during its active years.
-
Patent Landscape:
The patent is part of a dense ecosystem of compound, formulation, and method patents. Key competitors include Merck and GSK, with overlapping claims in similar therapeutic domains.
-
Legal & Commercial Implications:
While patent expiration around 2020 likely opened the market to generics, related patents, regulatory market exclusivities, and follow-up filings have continued to shape the competitive landscape.
-
Strategic Positioning:
The patent's foundational status underscores the importance of robust patent drafting and continuous innovation to sustain market exclusivity in highly competitive pharmaceutical sectors.
References
[1] US Patent 6,125,846, Pfizer Inc., "Heterocyclic Compounds and Methods of Use," granted September 26, 2000.
[2] USPTO Patent Database.
[3] MarketsandMarkets, "Antihypertensive Drugs Market," 2022.
[4] European Patent Office (EPO), Patent Register.
[5] WHO, "Global Status Report on Noncommunicable Diseases," 2014.
More… ↓
⤷ Start Trial
|
